Online ISSN: 1949-2553
www.oncotarget.com
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

LEARN MORE ABOUT ONCOTARGET

Targeting GITR in cancer immunotherapy – there is no perfect knowledge

News

June 21, 2023
PRESS RELEASE: On June 19, 2023, a new research perspective was published in Oncotarget, entitled, “Targeting GITR in cancer immunotherapy – there is no perfect knowledge.” continue reading »

Metformin’s Role in Preventing Metabolic Syndrome during Androgen Deprivation Therapy: A Phase II Study

News

June 20, 2023
PRESS RELEASE: On June 19, 2023, a new research paper was published in Oncotarget, entitled, “Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancer.” continue reading »

New Study Reveals Genetic Risk Factors for Cancer in Saudi Arabia

Oncotarget

June 16, 2023
In a new study, researchers found that 38.4% of a cohort in Saudi Arabia carried pathogenic variants linked to hereditary cancer risk. continue reading »

ACSL4: Biomarker, Mediator and Target in Quadruple Negative Breast Cancer

News

June 14, 2023
PRESS RELEASE: On June 12, 2023, a new review paper was published in Oncotarget, entitled, “ACSL4: biomarker, mediator and target in quadruple negative breast cancer.” continue reading »

LP-284 Targets Non-Hodgkin’s Lymphoma and DNA Damage Repair Deficiency

News

June 12, 2023
PRESS RELEASE: On June 12, 2023, a new research paper was published in Oncotarget, entitled, “LP-284, a small molecule acylfulvene, exerts potent antitumor activity in preclinical non-Hodgkin's lymphoma models and in cells deficient in DNA damage repair.” continue reading »